Deal Watch: Genentech Inks New Collaborations With Skyhawk, Convelo
Executive Summary
Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.
You may also be interested in...
Roche Inks RNA-Targeted Small Molecule Pact With Ribometrix
Deal snapshot: Roche’s third partnership around small molecule, RNA-targeted therapies taps Ribometrix’s three-dimensional structural analysis of RNA to find pockets amenable to small molecule drugs.
Vertex Inks RNA Splicing Pact With Skyhawk
In addition to its near-monopoly in cystic fibrosis, the US biotech behemoth is continuing its deal-making in other areas and has become the latest company to link up with Skyhawk.
Bristol Licenses Dragonfly’s IL-12 Program To Boost Immunotherapies
The new collaboration announced 17 August is worth up to $475m in near-term upfront payments plus undisclosed milestone fees and royalties up to 24%.